Literature DB >> 29950711

FDA approves Eli Lilly's baricitinib.

Asher Mullard.   

Abstract

Entities:  

Year:  2018        PMID： 29950711     DOI： 10.1038/nrd.2018.112

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.

Authors:  Shuai Shao; Lam C Tsoi; Mrinal K Sarkar; Xianying Xing; Ke Xue; Ranjitha Uppala; Celine C Berthier; Chang Zeng; Matthew Patrick; Allison C Billi; Joseph Fullmer; Maria A Beamer; Bethany Perez-White; Spiro Getsios; Andrew Schuler; John J Voorhees; Sung Choi; Paul Harms; J Michelle Kahlenberg; Johann E Gudjonsson
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

2.  Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.

Authors:  Matthew K Howe; Kennichi Dowdell; Hye Sun Kuehn; Qingxue Li; Geoffrey T Hart; Doreen Garabedian; Kelly Liepshutz; Amy P Hsu; Hua Su; Julie E Niemela; Jennifer L Stoddard; Gulbu Uzel; Evan Shereck; Laura Schulz; Tatyana Feldman; Sergio D Rosenzweig; Eric O Long; Lesia Dropulic; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

3.  Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.

Authors:  Ryan R Davis; Baoli Li; Sang Y Yun; Alice Chan; Pradeep Nareddy; Steven Gunawan; Muhammad Ayaz; Harshani R Lawrence; Gary W Reuther; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  J Med Chem       Date:  2021-02-11       Impact factor: 7.446

4.  Generation of a chemical genetic model for JAK3.

Authors:  Judit Remenyi; Rangeetha Jayaprakash Naik; Jinhua Wang; Momchil Razsolkov; Alyssa Verano; Quan Cai; Li Tan; Rachel Toth; Samantha Raggett; Carla Baillie; Ryan Traynor; C James Hastie; Nathanael S Gray; J Simon C Arthur
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 5.  Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2.

Authors:  Nilesh Gajanan Bajad; Swetha Rayala; Gopichand Gutti; Anjali Sharma; Meenakshi Singh; Ashok Kumar; Sushil Kumar Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-14

Review 6.  Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2.

Authors:  Xiang-Ning Zhang; Long-Ji Wu; Xia Kong; Bi-Ying Zheng; Zhe Zhang; Zhi-Wei He
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

7.  TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers.

Authors:  Angelina T Regua; Noah R Aguayo; Sara Abu Jalboush; Daniel L Doheny; Sara G Manore; Dongqin Zhu; Grace L Wong; Austin Arrigo; Calvin J Wagner; Yang Yu; Alexandra Thomas; Michael D Chan; Jimmy Ruiz; Guangxu Jin; Roy Strowd; Peiqing Sun; Jiayuh Lin; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

8.  Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Wenhui Xie; Shiyu Xiao; Yanrong Huang; Xiaoying Sun; Zhuoli Zhang
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-17       Impact factor: 5.346

Review 9.  Application of Baricitinib in Dermatology.

Authors:  Jingya Zhang; Fei Qi; Jie Dong; Yaqi Tan; Ling Gao; Fang Liu
Journal:  J Inflamm Res       Date:  2022-03-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.